EULAR 2023
Pushing the brake with a new treatment strategy
high5immunology.tv | Rheumatology | EULAR 2023
EULAR 2023
Pushing the brake with a new treatment strategy
EULAR 2023
Risk factors and prevention of arthritis
GESPIC, Early (SPACE)-cohort
EULAR 2023
Let's go for early treatment in axial envolvement?
BE COMPLETE, POETYK PSO PROGRAM
EUALR 2023
Treatment opportunities and what is new in PsA
EULAR 2023
Systemic inflammation in SpA /PsA
EULAR 2023
Which is the ideal instrument to assess disease…
Early (SPACE)-cohort
EULAR 2023
What is early axSpA?
EULAR 2023
Do NSAIDs modify the appearance of SIJ MRI?
EULAR 2023
Secukinumab vs Adalimumab on radiographic progression…
EULAR 2023
Data from clinical studies relevant for daily practice
Early (SPACE)-cohort
EULAR 2023
Clinically relevant findings for SpA detection
SURPASS
EULAR 2023
The effect of IL-17 inhibition on radiographic…
Early (SPACE)-cohort
EULAR 2023
Should we follow chronic back pts. suspected of early…
GESPIC
EULAR 2023
Factors associated with remission in early peripheral…
EULAR 2023
Definition of early axSpA
SURPASS
EULAR 2023
Effekt der IL-17 Inhibition auf die Röntgenprogression
EULAR 2023
Secukinumab vs Adalimumab dans la progression…
EULAR 2023
Definition consensuelle ASAS de la spondyloarthrite…
Early (SPACE)-cohort
EULAR 2023
Deberíamos seguir a los pacientes con dolor lumbar…
EULAR 2023
Daten aus klinischen Studien für die tägliche Praxis
EULAR 2023
Los AINES modifican la expresión de la RM de…
Early (SPACE)-cohort
EULAR 2023
Was ist frühe axSpA?
GESPIC
EULAR 2023
Facteurs associés à l’obtention d’une rémission dans la…
Early (SPACE)-cohort
EULAR 2023
Klinisch wichtige Befunde zur SpA-Erkennung
EULAR 2023
Qual'e lo strumento ideale per la valutazione di…
EULAR 2023
Differences between sex and gender in PsA
EULAR 2023
Higher comorbiditiy burden in PsA vs RA
EULAR 2023
Points to consider in PsA!
RABBIT-SpA
EULAR 2023
No need of MTX again and again and...
SIRENA
EULAR 2023
Early therapy in PsA is predictive
EULAR 2023
Deucravacitinib - effective and safe
RABBIT-SPA
EULAR 2023
MTX + Biologica in PsA
BE COMPLETE
EULAR 2023
Dual inhibition of IL-17A and IL-17F: a new option in…
EULAR 2023
Systemic inflammation objectively detectable
SIRENA
EULAR 2023
Frühe Therapie bei PsA prädiktiv
EULAR 2023
Mehr Komorbiditäten bei PsA als bei RA
EULAR 2023
Sytemische Inflammation objektiv erkennbar
BE COMPLETE
EULAR 2023
Duale Inhibition A und F: neue Option für PsA
EULAR 2023
Deucravacitinib - effektiv und sicher
EULAR 2023
Points to consider bei PsA
EULAR 2023
Differenze di genere nell'Artrite Psoriasi
RABBIT-SPA
EULAR 2023
MTX + Biologica bei PsA
RABBIT-SpA
EULAR 2023
Nicht schon wieder MTX...
EULAR 2023
Putting a focus on TDM
"JAK-POT" study
EULAR 2023
Update on JAKi safety
EULAR 2023
Pushing the brake with a new treatment strategy
APPIPRA
EULAR 2023
Prevention - should we treat pre-arthitis?
ORAL Surveillance
EULAR 2023
Keeping an eye on the lung!
APPIPRA
EULAR 2023
Preventing RA
EULAR 2023
Peresolimab - a new therapeutic principle in…
"JAK-POT" study
EULAR 2023
Major adverse cardiovascular events in patients on…
EULAR 2023
Pooled safety analysis of filgotinib
EULAR 2023
Difficult to treat and poly-refractory RA in a clinical…
EULAR 2023
Lung involvement in RA
EULAR 2023
Corticoid bridging in RA - useful and safe
EULAR 2023
The IL-23 pathway
EULAR 2023
What is new in RA?
EULAR 2023
Peresolimab - ein neues Therapieprinzip für die…
EULAR 2023
AR difícil de tratar y polirrefractaria en la practica…
"JAK-POT" study
EULAR 2023
Kardiovaskulære hendelser hos pasienter behandlet med…
EULAR 2023
Tratamiento con glucocorticoides al inicio del FAME -…
EULAR 2023
Development of EMM in SpA patients treated with…
EULAR 2023
Incidence of ILD in patients with RA and PsA
EULAR 2023
Overview of treatment recommendations in PsA and axSpA
EULAR 2023
Immunogenicity in Adalimumab - real-world data
EULAR 2023
To stop or not to stop TNF-inhibitors after pregnancy…
EULAR 2023
Arthritis therapy under checkpoint-inhibition
NOR-DRUM A+B
EULAR 2023
Measurement of anti-drug antibodies in rheumatology
EULAR 2023
Interrompere o non interrompere gli anti-TNF dopo la…
EULAR 2023
Therapie der Arthritis unter Checkpoint-Inhibitoren
EULAR 2023
Insidens av interstitiell lungesykdom hos pasienter med…
EULAR 2023
Aspetti principali delle raccomandazioni per l'Artrite…
EULAR 2023
Immunogenisitet hos pasienter behandlet med adalimumab…
NOR-DRUM A+B
EULAR 2023
Messung von Anti-drug Antibodies in der Rheumatologie
EULAR 2023
Desarrollo de MEM en pacientes con EspA tratados con…
EULAR 2023
Cardiovascular disease and long-term use of NSAIDs in…
EULAR 2023
Childhood infections, perinatal factors, and the risk…
EULAR 2023
Infezioni infantili, fattori perinatali e rischio di…
EULAR 2023
Rischio cardiovascolare e utilizzo prolungato di fans…
EULAR 2023
New promising strategies in Lupus and Sjögren's…
EULAR 2023
Update on CAR-T cells!
EULAR 2023
1-year data on CAR-T cell therapy in lupus
EULAR 2023
JAK inhibition and BTK-JAK inhibition in lupus
EULAR 2023
Telitacicept in lupus
EULAR 2023
JAK-Inhibition und BTK-JAK-Inhibition bei Lupus
EULAR 2023
Aktuelles zur CAR-T-Zelltherapie!
EULAR 2023
1-Jahres Daten zur CAR-T-Zell Therapie beim Lupus
EULAR 2023
Telitacicept beim Lupus
EULAR 2023
Telitacicept in Sjögren's Syndrome
EULAR 2023
Telitacicept beim Sjögren Syndrom
EULAR 2023
IL-17 isoforms in enthesitis
EULAR 2023
COVID-19: a pandemic with a long tail
EULAR 2023
IL-17-Isoformen bei Enthesitis
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!